Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers
Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of...
Uloženo v:
| Vydáno v: | Journal of nanobiotechnology Ročník 19; číslo 1; s. 59 - 27 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
25.02.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1477-3155, 1477-3155 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review. |
|---|---|
| AbstractList | Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review. Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review. Keywords: Virus-like particles (VLPs), Subunit vaccine, Expression and purification platforms, Infectious disease vaccine, Cancer vaccine, Immune response Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review.Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review. Abstract Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review. |
| ArticleNumber | 59 |
| Audience | Academic |
| Author | Hajizade, Abbas Ahmadian, Gholamreza Nooraei, Saghi Bahrulolum, Howra Hoseini, Zakieh Sadat Easton, Andrew J. Katalani, Camellia |
| Author_xml | – sequence: 1 givenname: Saghi surname: Nooraei fullname: Nooraei, Saghi organization: Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB) – sequence: 2 givenname: Howra surname: Bahrulolum fullname: Bahrulolum, Howra organization: Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB) – sequence: 3 givenname: Zakieh Sadat surname: Hoseini fullname: Hoseini, Zakieh Sadat organization: Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB) – sequence: 4 givenname: Camellia surname: Katalani fullname: Katalani, Camellia organization: Sari Agriculture Science and Natural Resource University (SANRU), Genetics and Agricultural Biotechnology Institute of Tabarestan (GABIT) – sequence: 5 givenname: Abbas surname: Hajizade fullname: Hajizade, Abbas organization: Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences – sequence: 6 givenname: Andrew J. surname: Easton fullname: Easton, Andrew J. email: a.j.easton@warwick.ac.uk organization: School of Life Sciences, Gibbet Hill Campus, University of Warwick – sequence: 7 givenname: Gholamreza surname: Ahmadian fullname: Ahmadian, Gholamreza email: ahmadian@nigeb.ac.ir organization: Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33632278$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltr3DAQhU1JaS7tH-hDMfSlhTrV3VYfCiH0shAo9PYqZHnkaOuVtpIdmn9feXfTZEMJxlgzOueTNZzj4sAHD0XxHKNTjBvxNmEiOa4QyS9qkKjqR8URZnVdUcz5wZ31YXGc0hIhQhhhT4pDSgUlpG6Oiv6ni1OqBvcLyrWOozMDpHflOkKu9OiCf1O61WryoQfvjBuvS-27crwEF8sYsrjUqfTahyttjPNznfe7OPWbrtExOojpafHY6iHBs933pPjx8cP388_VxZdPi_Ozi8oIhsdK6lrKVrac1EI2wmJhrTSAJMJWUE7E3Ea5prRriBQgqSWC8JYJrAE0PSkWW24X9FKto1vpeK2CdmrTCLFXu1sqXSPGDUiUz2JagtaW54HS1tat4cxm1vstaz21K-gM-DHqYQ-6v-PdperDlaol4rLhGfBqB4jh9wRpVCuXDAyD9hCmpAiTjCIkSJ2lL-9Jl2GKPo9KEY5Iw2rM-K2q1_kCztuQzzUzVJ0JToWglM6s0_-o8tPBypmcIetyf8_wes-QNSP8GXs9paQW377ua1_cHcq_adxEKguarcDEkFIEq3JqNknKf-EGhZGa06u26VU5vWqTXjWzyT3rDf1BE92aUhb7HuLt5B5w_QWpP_-T |
| CitedBy_id | crossref_primary_10_1111_bcp_15552 crossref_primary_10_3390_vaccines10111946 crossref_primary_10_1007_s11596_021_2395_1 crossref_primary_10_3390_biologics4010001 crossref_primary_10_3390_pharmaceutics15112623 crossref_primary_10_1016_j_vetmic_2025_110487 crossref_primary_10_1021_acsnano_5c06081 crossref_primary_10_1038_s41541_023_00754_3 crossref_primary_10_1080_00439339_2025_2461723 crossref_primary_10_3390_vaccines13030216 crossref_primary_10_3390_ijms23158579 crossref_primary_10_3390_vetsci11060264 crossref_primary_10_1016_j_nwnano_2024_100058 crossref_primary_10_1007_s12032_025_02853_8 crossref_primary_10_1002_smll_202412218 crossref_primary_10_1016_j_ijpharm_2025_125848 crossref_primary_10_3390_vaccines13080829 crossref_primary_10_1093_nsr_nwad310 crossref_primary_10_3390_pharmaceutics13122000 crossref_primary_10_1007_s11095_024_03698_y crossref_primary_10_1016_j_aqrep_2024_102546 crossref_primary_10_3389_fbioe_2023_1096363 crossref_primary_10_3390_pharmaceutics16020292 crossref_primary_10_1002_jctb_7105 crossref_primary_10_3389_fimmu_2022_864718 crossref_primary_10_1016_j_addr_2022_114142 crossref_primary_10_1016_j_ijbiomac_2025_145158 crossref_primary_10_3390_vaccines13090989 crossref_primary_10_3390_vaccines9121409 crossref_primary_10_1002_bit_28558 crossref_primary_10_1002_med_22097 crossref_primary_10_1016_j_fbio_2025_107272 crossref_primary_10_1039_D2NR07071E crossref_primary_10_1007_s00299_025_03602_x crossref_primary_10_1016_j_vaccine_2022_09_009 crossref_primary_10_2174_1381612828666220701160116 crossref_primary_10_34133_research_0761 crossref_primary_10_1038_s41598_023_47068_x crossref_primary_10_1016_j_xcrp_2025_102814 crossref_primary_10_1371_journal_pone_0290046 crossref_primary_10_3389_fbioe_2022_1106767 crossref_primary_10_1007_s12257_024_00089_3 crossref_primary_10_3390_life12020156 crossref_primary_10_1016_j_pep_2022_106106 crossref_primary_10_1186_s12951_021_01234_3 crossref_primary_10_3390_life13030617 crossref_primary_10_3389_fbioe_2024_1456453 crossref_primary_10_1016_j_procbio_2022_10_020 crossref_primary_10_3390_v15040878 crossref_primary_10_3389_fchem_2022_990171 crossref_primary_10_1038_s41541_024_00871_7 crossref_primary_10_1016_j_chroma_2025_465851 crossref_primary_10_3390_cancers14184490 crossref_primary_10_3390_vaccines11020436 crossref_primary_10_1016_j_virol_2023_01_017 crossref_primary_10_1128_msystems_00927_22 crossref_primary_10_3390_ijms232415684 crossref_primary_10_1051_e3sconf_202450902005 crossref_primary_10_3390_ijms252212346 crossref_primary_10_1038_s41598_024_76163_w crossref_primary_10_1007_s12274_024_6748_5 crossref_primary_10_3390_ijms24054907 crossref_primary_10_1186_s12967_025_06435_0 crossref_primary_10_1007_s00203_023_03629_2 crossref_primary_10_1002_smll_202207892 crossref_primary_10_1016_j_jconrel_2023_03_045 crossref_primary_10_3389_fimmu_2024_1453753 crossref_primary_10_1021_acs_biomac_5c00593 crossref_primary_10_3390_plants10122558 crossref_primary_10_1038_s41598_025_10792_7 crossref_primary_10_3389_fimmu_2024_1504124 crossref_primary_10_3390_vaccines9090988 crossref_primary_10_3390_pathogens12101259 crossref_primary_10_1007_s00705_022_05653_x crossref_primary_10_1007_s00449_022_02754_4 crossref_primary_10_1016_j_tvjl_2024_106097 crossref_primary_10_1016_j_hsr_2023_100112 crossref_primary_10_1089_rej_2024_0034 crossref_primary_10_1021_acssynbio_4c00773 crossref_primary_10_1016_j_mser_2023_100715 crossref_primary_10_3390_ijms241914622 crossref_primary_10_3390_vaccines11081304 crossref_primary_10_1002_btpr_3292 crossref_primary_10_3390_ijms26136462 crossref_primary_10_1016_j_mtchem_2022_100808 crossref_primary_10_1186_s12967_023_04843_8 crossref_primary_10_1016_j_vetmic_2023_109971 crossref_primary_10_1186_s13045_025_01692_4 crossref_primary_10_3390_v15040819 crossref_primary_10_3390_vaccines12010030 crossref_primary_10_3389_fbioe_2024_1367405 crossref_primary_10_71150_jm_2410018 crossref_primary_10_22270_jddt_v15i8_7314 crossref_primary_10_3390_ijms24129972 crossref_primary_10_1186_s13567_024_01383_x crossref_primary_10_1016_j_vaccine_2023_12_077 crossref_primary_10_3389_fcimb_2022_997875 crossref_primary_10_1016_j_vaccine_2023_11_048 crossref_primary_10_3389_fmolb_2022_975054 crossref_primary_10_3389_fonc_2023_1211262 crossref_primary_10_1186_s13568_023_01617_9 crossref_primary_10_3390_ijms241914631 crossref_primary_10_1002_mabi_202400088 crossref_primary_10_3389_fpls_2021_717952 crossref_primary_10_1002_smll_202502315 crossref_primary_10_1016_j_microb_2025_100351 crossref_primary_10_1080_21645515_2024_2399915 crossref_primary_10_1186_s12951_024_02837_2 crossref_primary_10_3389_fimmu_2025_1625670 crossref_primary_10_3389_fpls_2023_1170815 crossref_primary_10_1016_j_cocis_2023_101703 crossref_primary_10_1016_j_micpath_2025_108055 crossref_primary_10_1186_s12934_024_02497_9 crossref_primary_10_1186_s12985_025_02666_1 crossref_primary_10_3389_fcimb_2025_1596955 crossref_primary_10_3390_v14061195 crossref_primary_10_3390_vaccines13070731 crossref_primary_10_3390_vaccines9080920 crossref_primary_10_3390_vaccines11050941 crossref_primary_10_1007_s00253_025_13436_y crossref_primary_10_3390_vaccines11091438 crossref_primary_10_1016_j_heliyon_2024_e33142 crossref_primary_10_1002_bit_28419 crossref_primary_10_1002_slct_202403627 crossref_primary_10_1016_j_xphs_2021_12_011 crossref_primary_10_1186_s12934_023_02259_z crossref_primary_10_7554_eLife_98579 crossref_primary_10_1021_jacs_3c02679 crossref_primary_10_1016_j_copbio_2022_102888 crossref_primary_10_1039_D5PM00017C crossref_primary_10_1007_s12374_023_09393_6 crossref_primary_10_1080_21645515_2022_2045853 crossref_primary_10_3390_ijms25168746 crossref_primary_10_1186_s12934_023_02043_z crossref_primary_10_1016_j_vaccine_2022_03_059 crossref_primary_10_3390_v16071093 crossref_primary_10_1186_s12951_023_01866_7 crossref_primary_10_1038_s41525_023_00387_4 crossref_primary_10_1016_j_vaccine_2024_04_048 crossref_primary_10_1016_j_imj_2025_100165 crossref_primary_10_3390_pharmaceutics17091183 crossref_primary_10_1016_j_ijbiomac_2024_134027 crossref_primary_10_1177_00220345231164111 crossref_primary_10_1002_bit_28703 crossref_primary_10_1016_j_addr_2023_114826 crossref_primary_10_3390_ijms24119225 crossref_primary_10_3389_fdgth_2021_745674 crossref_primary_10_3389_fimmu_2023_1161149 crossref_primary_10_1002_jssc_202100947 crossref_primary_10_1021_acsnano_4c18021 crossref_primary_10_1371_journal_pone_0283928 crossref_primary_10_3390_vaccines12091002 crossref_primary_10_1038_s41541_025_01254_2 crossref_primary_10_3390_v16060834 crossref_primary_10_15212_ZOONOSES_2023_0018 crossref_primary_10_3390_vaccines12091007 crossref_primary_10_1007_s11356_022_22661_1 crossref_primary_10_7554_eLife_98579_3 crossref_primary_10_1146_annurev_bioeng_110122_124359 crossref_primary_10_1186_s12964_023_01104_5 crossref_primary_10_3389_fbioe_2022_917746 crossref_primary_10_1016_j_vaccine_2025_127394 crossref_primary_10_1055_a_2586_3974 crossref_primary_10_3390_vaccines11111641 crossref_primary_10_3390_molecules28176201 crossref_primary_10_1089_crispr_2022_0051 crossref_primary_10_1186_s12951_024_02311_z crossref_primary_10_1016_j_intimp_2022_109650 crossref_primary_10_1073_pnas_2424678122 crossref_primary_10_1038_s41392_024_01745_z crossref_primary_10_3390_v14081684 crossref_primary_10_1097_CCO_0000000000000828 crossref_primary_10_3390_ijms241612963 crossref_primary_10_3390_v15102123 crossref_primary_10_3390_v17091209 crossref_primary_10_3390_cancers14163842 crossref_primary_10_2147_IJN_S269986 crossref_primary_10_1002_smll_202303713 crossref_primary_10_3390_pr9111996 crossref_primary_10_1093_lifemedi_lnae031 crossref_primary_10_1038_s42003_025_08579_7 crossref_primary_10_1016_j_jia_2024_09_024 crossref_primary_10_1007_s12011_025_04533_0 crossref_primary_10_1016_j_jconrel_2025_113827 crossref_primary_10_1002_anbr_202200010 crossref_primary_10_3390_v14050943 crossref_primary_10_3390_cells11071182 crossref_primary_10_1016_j_ijpharm_2025_125470 crossref_primary_10_1073_pnas_2426094122 crossref_primary_10_1080_1040841X_2025_2492154 crossref_primary_10_32604_or_2024_056955 crossref_primary_10_1002_elps_202100124 crossref_primary_10_1016_j_mattod_2023_04_011 crossref_primary_10_1039_D3NH00195D crossref_primary_10_1016_j_intimp_2024_113784 crossref_primary_10_1007_s10616_023_00598_8 crossref_primary_10_1016_j_mattod_2023_04_008 crossref_primary_10_1089_hum_2024_258 crossref_primary_10_1016_j_jconrel_2024_02_027 crossref_primary_10_1016_j_vetmic_2024_110249 crossref_primary_10_1016_j_jfutfo_2023_05_006 crossref_primary_10_3390_v17020148 crossref_primary_10_3389_fimmu_2024_1505612 crossref_primary_10_1016_j_eurpolymj_2025_113876 crossref_primary_10_1021_acsami_5c12494 crossref_primary_10_1021_acs_jafc_5c01254 crossref_primary_10_3389_fimmu_2024_1387811 crossref_primary_10_1016_j_drup_2024_101098 crossref_primary_10_3389_fbioe_2024_1499474 crossref_primary_10_3390_vaccines10071120 crossref_primary_10_1093_biomethods_bpaf019 crossref_primary_10_1111_apm_13284 crossref_primary_10_3390_vaccines10071124 crossref_primary_10_1016_j_bpc_2022_106943 crossref_primary_10_1038_s41423_022_00897_8 crossref_primary_10_2147_IJN_S455213 crossref_primary_10_3390_vaccines11121768 crossref_primary_10_3389_fcvm_2022_1037741 crossref_primary_10_1016_j_ijbiomac_2025_141152 crossref_primary_10_3390_vaccines12060661 crossref_primary_10_1016_j_cell_2024_03_007 crossref_primary_10_1002_adtp_202300082 crossref_primary_10_3390_v15102013 crossref_primary_10_1002_bit_28914 crossref_primary_10_36233_0372_9311_661 crossref_primary_10_4014_jmb_2407_07033 crossref_primary_10_1080_13102818_2025_2457691 crossref_primary_10_3390_v16010013 crossref_primary_10_3390_vaccines11050992 crossref_primary_10_4155_tde_2023_0074 crossref_primary_10_3390_v15051095 crossref_primary_10_54097_6s5qzf94 crossref_primary_10_3389_fnano_2024_1506665 crossref_primary_10_1016_j_apsb_2025_05_007 crossref_primary_10_1002_smsc_202500270 crossref_primary_10_1038_s41541_024_01035_3 crossref_primary_10_3390_ph16010096 crossref_primary_10_1186_s12985_022_01844_9 crossref_primary_10_1016_j_vaccine_2025_127206 crossref_primary_10_1016_j_bpc_2024_107375 crossref_primary_10_3390_vaccines11040733 crossref_primary_10_3390_vaccines13070695 crossref_primary_10_2174_0115733947308351240514182503 crossref_primary_10_1186_s13071_023_05755_8 crossref_primary_10_1002_smll_202407649 crossref_primary_10_3390_vaccines12091020 crossref_primary_10_3390_plants13243564 crossref_primary_10_1007_s11259_023_10290_z crossref_primary_10_1016_j_ijbiomac_2023_124478 crossref_primary_10_1208_s12249_025_03053_3 crossref_primary_10_3390_v15091786 crossref_primary_10_3390_vaccines13060556 crossref_primary_10_3389_fbioe_2024_1399938 crossref_primary_10_3390_biom14081036 crossref_primary_10_3390_pharmaceutics15051538 crossref_primary_10_1002_ajh_26659 crossref_primary_10_1002_bit_28937 crossref_primary_10_1038_s41565_022_01146_9 crossref_primary_10_3390_pharmaceutics17091175 crossref_primary_10_1016_j_omto_2022_02_010 crossref_primary_10_1002_ange_202216097 crossref_primary_10_1002_ijch_202200030 crossref_primary_10_3389_fimmu_2024_1332939 crossref_primary_10_3390_pharmaceutics16121549 crossref_primary_10_3389_fimmu_2024_1455211 crossref_primary_10_1134_S0026893324700043 crossref_primary_10_3390_vaccines11081373 crossref_primary_10_1007_s12015_024_10689_4 crossref_primary_10_3390_vaccines12091033 crossref_primary_10_1002_EXP_20210082 crossref_primary_10_3390_pharmaceutics17050655 crossref_primary_10_1016_j_ijbiomac_2023_124582 crossref_primary_10_3390_vaccines11040751 crossref_primary_10_3390_vaccines12121375 crossref_primary_10_3390_vaccines9101129 crossref_primary_10_1186_s44149_024_00119_w crossref_primary_10_1038_s41590_022_01132_2 crossref_primary_10_1080_21645515_2024_2317439 crossref_primary_10_3389_fmicb_2023_1154990 crossref_primary_10_1002_cmdc_202400491 crossref_primary_10_1002_jmv_28503 crossref_primary_10_1155_2023_4588659 crossref_primary_10_3390_molecules30122536 crossref_primary_10_1016_j_chroma_2025_466358 crossref_primary_10_1186_s12985_024_02322_0 crossref_primary_10_3389_fbioe_2023_1192050 crossref_primary_10_3390_v14122825 crossref_primary_10_1016_j_bej_2024_109379 crossref_primary_10_3390_vaccines10091447 crossref_primary_10_3390_bios15060390 crossref_primary_10_3389_fimmu_2023_1088852 crossref_primary_10_3390_ijms25073736 crossref_primary_10_1016_j_jconrel_2022_12_022 crossref_primary_10_1016_j_omtn_2024_102280 crossref_primary_10_1186_s13568_022_01353_6 crossref_primary_10_1016_j_bej_2023_109062 crossref_primary_10_1016_j_phrs_2024_107341 crossref_primary_10_1016_j_visres_2023_108273 crossref_primary_10_1186_s13071_023_06020_8 crossref_primary_10_2147_IJN_S450853 crossref_primary_10_1186_s12951_022_01545_z crossref_primary_10_7759_cureus_46354 crossref_primary_10_1021_acsnano_5c07748 crossref_primary_10_3390_pharmaceutics14091973 crossref_primary_10_1146_annurev_virology_100220_010653 crossref_primary_10_1002_adma_202308029 crossref_primary_10_1002_anie_202214001 crossref_primary_10_1016_j_ejps_2023_106460 crossref_primary_10_3390_ijms26146879 crossref_primary_10_1002_adhm_202201583 crossref_primary_10_1080_17435889_2025_2518915 crossref_primary_10_3389_fpubh_2025_1611028 crossref_primary_10_3390_vaccines11111704 crossref_primary_10_3389_fvets_2023_1243835 crossref_primary_10_3390_life12121968 crossref_primary_10_3389_fbioe_2022_805176 crossref_primary_10_1093_procel_pwaf026 crossref_primary_10_3390_v16050659 crossref_primary_10_1038_s41541_025_01105_0 crossref_primary_10_3389_fimmu_2023_1192821 crossref_primary_10_1007_s00705_025_06339_w crossref_primary_10_1016_j_cej_2024_157746 crossref_primary_10_1021_acs_molpharmaceut_5c00251 crossref_primary_10_3390_ijms241512054 crossref_primary_10_3390_pathogens10111477 crossref_primary_10_3390_ijms242015484 crossref_primary_10_3390_v14091905 crossref_primary_10_1016_j_isci_2025_112599 crossref_primary_10_1002_med_21997 crossref_primary_10_1002_adbi_202400374 crossref_primary_10_1038_s41598_021_91328_7 crossref_primary_10_1038_s43586_023_00200_7 crossref_primary_10_3390_vaccines11071172 crossref_primary_10_3389_fimmu_2022_986823 crossref_primary_10_1016_j_ijbiomac_2022_01_108 crossref_primary_10_1016_j_heliyon_2024_e34927 crossref_primary_10_3390_vaccines10050819 crossref_primary_10_1002_adtp_202300360 crossref_primary_10_1016_j_vaccine_2024_126483 crossref_primary_10_1007_s12268_024_2112_2 crossref_primary_10_1038_s41598_024_53624_w crossref_primary_10_3390_vaccines12121345 crossref_primary_10_1002_adtp_202300005 crossref_primary_10_3390_ijms25126699 crossref_primary_10_3389_fimmu_2025_1573037 crossref_primary_10_1134_S0026893322010022 crossref_primary_10_1007_s00253_025_13560_9 crossref_primary_10_3390_v16081341 crossref_primary_10_3389_fimmu_2023_1123805 crossref_primary_10_1016_j_semcancer_2021_06_021 crossref_primary_10_1016_j_addr_2025_115681 crossref_primary_10_3389_fbioe_2022_1052436 crossref_primary_10_1007_s00216_022_04104_5 crossref_primary_10_1007_s11051_022_05452_0 crossref_primary_10_2217_nnm_2022_0082 crossref_primary_10_1007_s40259_022_00544_8 crossref_primary_10_3390_vaccines9060554 crossref_primary_10_1186_s12951_024_02767_z crossref_primary_10_3390_jfb13040304 crossref_primary_10_1038_s41467_025_58364_7 crossref_primary_10_3390_vaccines11121828 crossref_primary_10_1016_j_jcyt_2025_05_010 crossref_primary_10_1016_j_virusres_2023_199235 crossref_primary_10_1038_s41526_024_00378_4 crossref_primary_10_1615_CritRevTherDrugCarrierSyst_2025053265 crossref_primary_10_1016_j_bej_2023_109013 crossref_primary_10_3390_ijms24119270 crossref_primary_10_1007_s11095_022_03301_2 crossref_primary_10_3390_ijms24098060 crossref_primary_10_1080_14760584_2025_2452955 crossref_primary_10_1016_j_ijpharm_2024_123923 crossref_primary_10_1007_s11696_023_03271_8 crossref_primary_10_1002_advs_202411278 crossref_primary_10_3233_JCB_240155 crossref_primary_10_3390_v14071553 crossref_primary_10_1111_1748_5967_70039 crossref_primary_10_3389_fbioe_2021_642794 crossref_primary_10_1016_j_ijpharm_2025_126096 crossref_primary_10_15832_ankutbd_1622082 crossref_primary_10_1186_s12951_022_01610_7 crossref_primary_10_3390_vaccines12111290 crossref_primary_10_1080_1061186X_2023_2288996 crossref_primary_10_3390_vaccines9121490 crossref_primary_10_1016_j_vetmic_2023_109776 crossref_primary_10_3389_fimmu_2023_1131057 crossref_primary_10_1016_j_ccr_2025_216806 crossref_primary_10_1097_MS9_0000000000001674 crossref_primary_10_3390_vaccines13090900 crossref_primary_10_1016_j_jconrel_2024_10_031 crossref_primary_10_1038_s41541_025_01216_8 crossref_primary_10_3390_vaccines13090909 crossref_primary_10_3389_fimmu_2022_906275 crossref_primary_10_3390_cells13141214 crossref_primary_10_3389_fimmu_2021_804416 crossref_primary_10_3389_fimmu_2023_1201136 crossref_primary_10_3389_fphar_2023_1173251 crossref_primary_10_14309_ctg_0000000000000659 crossref_primary_10_1016_j_virol_2022_10_008 crossref_primary_10_3390_bioengineering12090956 crossref_primary_10_3390_vaccines10020315 crossref_primary_10_3390_molecules28227679 crossref_primary_10_1016_j_ymthe_2024_10_029 crossref_primary_10_1002_adtp_202400223 crossref_primary_10_3389_fimmu_2025_1651594 crossref_primary_10_1016_j_virol_2025_110510 crossref_primary_10_1016_j_jcis_2022_12_090 crossref_primary_10_3389_fbioe_2024_1475918 crossref_primary_10_3389_fvets_2024_1460973 crossref_primary_10_1007_s00284_024_03750_5 crossref_primary_10_3389_fimmu_2023_1238649 crossref_primary_10_3390_ijms25137429 crossref_primary_10_1016_j_vacune_2023_07_005 crossref_primary_10_1007_s10238_024_01425_w crossref_primary_10_1038_s41541_025_01147_4 crossref_primary_10_12688_f1000research_72956_2 crossref_primary_10_12688_f1000research_72956_3 crossref_primary_10_1002_cam4_6099 crossref_primary_10_12688_f1000research_72956_1 crossref_primary_10_1016_j_ijbiomac_2023_123979 crossref_primary_10_12688_f1000research_72956_4 crossref_primary_10_3390_vaccines10030478 crossref_primary_10_1016_j_virol_2025_110627 crossref_primary_10_12688_f1000research_72956_5 crossref_primary_10_1016_j_chroma_2024_464975 crossref_primary_10_3390_vaccines13020126 crossref_primary_10_1002_anie_202216097 crossref_primary_10_1002_smll_202401631 crossref_primary_10_3390_cells10112949 crossref_primary_10_59717_j_xinn_med_2024_100081 crossref_primary_10_1128_spectrum_00013_24 crossref_primary_10_3390_vaccines11010102 crossref_primary_10_3390_v14030636 crossref_primary_10_1016_j_ijpharm_2025_126180 crossref_primary_10_1186_s12951_022_01710_4 crossref_primary_10_1007_s40820_023_01153_y crossref_primary_10_3390_vaccines10020227 crossref_primary_10_1111_raq_12916 crossref_primary_10_3390_cells11111843 crossref_primary_10_1002_bit_28118 crossref_primary_10_3390_pharmaceutics15010231 crossref_primary_10_1038_s41573_023_00762_x crossref_primary_10_1111_1348_0421_13182 crossref_primary_10_70749_ijbr_v3i1_501 crossref_primary_10_3389_fbioe_2025_1631807 crossref_primary_10_3390_bioengineering9110713 crossref_primary_10_3390_vaccines12080927 crossref_primary_10_3389_fonc_2025_1549809 crossref_primary_10_1002_ange_202214001 crossref_primary_10_1038_s41598_023_28790_y crossref_primary_10_1016_j_addr_2023_115042 crossref_primary_10_1016_j_jconrel_2022_01_013 crossref_primary_10_3390_vaccines11091506 crossref_primary_10_1016_j_bmt_2025_100069 crossref_primary_10_1002_biot_202300191 crossref_primary_10_3389_fvets_2024_1405605 crossref_primary_10_3389_fimmu_2025_1557415 crossref_primary_10_3389_fmicb_2021_790121 crossref_primary_10_1080_1061186X_2024_2416241 crossref_primary_10_1002_smll_202402980 crossref_primary_10_3390_pharmaceutics15071931 crossref_primary_10_1002_advs_202202797 crossref_primary_10_1002_wnan_1923 crossref_primary_10_1016_j_addr_2023_115134 crossref_primary_10_1016_j_jchromb_2025_124539 crossref_primary_10_1038_s41573_024_01086_0 crossref_primary_10_3390_ijms242317056 crossref_primary_10_1016_j_biomaterials_2025_123314 crossref_primary_10_3390_vaccines12030267 crossref_primary_10_1007_s12015_023_10585_3 crossref_primary_10_1016_j_vaccine_2022_06_079 crossref_primary_10_1016_j_virol_2022_11_012 crossref_primary_10_1080_21645515_2021_1995283 crossref_primary_10_1016_j_copbio_2022_102807 crossref_primary_10_3390_pharmaceutics16020247 crossref_primary_10_1002_adma_202307822 crossref_primary_10_1016_j_smaim_2025_01_002 crossref_primary_10_1016_j_jpba_2022_115089 crossref_primary_10_1021_acsphotonics_5c00736 crossref_primary_10_3390_cells11111825 crossref_primary_10_1186_s43094_023_00515_y crossref_primary_10_3390_vaccines11020479 crossref_primary_10_1016_j_mtbio_2025_102116 crossref_primary_10_3390_vaccines12080829 crossref_primary_10_1002_rpm_20240006 crossref_primary_10_1016_j_addr_2023_115141 crossref_primary_10_1039_D2BM00011C crossref_primary_10_1002_biot_202300199 crossref_primary_10_3390_ijms24021533 crossref_primary_10_1002_advs_202303049 |
| Cites_doi | 10.1016/j.febslet.2007.03.060 10.1358/dot.2018.54.7.2833984 10.7150/thno.30977 10.1586/erv.12.153 10.1016/S0042-6822(02)00028-4 10.1016/S0140-6736(10)61030-6 10.1086/520612 10.1186/s40425-018-0484-x 10.1056/NEJMoa2026920 10.1038/s41467-018-08265-9 10.1016/j.virol.2006.12.014 10.1007/s00280-014-2560-3 10.1371/journal.pone.0009784 10.4049/jimmunol.1103312 10.1016/j.vaccine.2008.01.058 10.1371/journal.pone.0002685 10.1016/j.jbiotec.2005.03.026 10.1186/1743-422X-9-52 10.1111/j.1492-7535.2005.01155.x 10.1128/CVI.00304-06 10.1186/s13036-019-0206-z 10.4049/jimmunol.171.5.2242 10.1371/journal.pntd.0004782 10.3390/ijms17101715 10.1146/annurev.iy.11.040193.001555 10.3389/fimmu.2019.01015 10.1006/mthe.2000.0217 10.1016/S0264-410X(02)00266-9 10.1073/pnas.1206970109 10.4049/jimmunol.173.3.1951 10.1016/j.vaccine.2008.01.053 10.1615/CritRevTherDrugCarrierSyst.2020033273 10.1007/s12033-012-9598-4 10.1084/jem.155.3.768 10.4161/hv.18757 10.1016/S0168-1656(02)00364-4 10.1586/erv.09.163 10.1016/j.micpath.2015.08.013 10.1016/j.tim.2010.11.003 10.1128/jvi.67.12.6929-6936.1993 10.1182/bloodadvances.2018027268 10.1038/sj.bjc.6604677 10.1016/j.vaccine.2011.12.081 10.1016/j.vaccine.2010.04.025 10.1038/s41598-019-41522-5 10.1016/j.nano.2010.04.005 10.1016/j.celrep.2017.10.016 10.1021/bc1002532 10.1128/JVI.01930-17 10.1089/vim.2005.18.244 10.1084/jem.193.8.881 10.1016/j.virol.2009.11.001 10.1016/S0140-6736(20)32010-9 10.1016/j.jip.2011.05.004 10.1016/j.nano.2012.01.007 10.1073/pnas.79.19.5818 10.1128/AEM.72.1.745-752.2006 10.1038/s41467-017-00090-w 10.1007/s12250-011-3209-6 10.33073/pjm-2015-001 10.1371/journal.pone.0068303 10.1126/science.3952490 10.2217/17460794.3.1.83 10.1371/journal.pone.0190868 10.1016/j.nano.2014.07.009 10.1111/j.1467-7652.2009.00496.x 10.1128/JVI.01861-10 10.1016/j.vaccine.2019.06.002 10.1371/journal.pone.0104523 10.3389/fimmu.2019.00592 10.1021/nn201397z 10.1371/journal.pone.0005569 10.1128/JVI.00129-19 10.1093/intimm/dxw015 10.4149/av_2013_02_123 10.1016/j.jbiotec.2011.04.011 10.1016/S0042-6822(03)00141-7 10.12688/f1000research.18749.1 10.3389/fbioe.2020.00489 10.18388/abp.2016_1275 10.1016/j.vaccine.2015.11.032 10.4161/hv.6.5.11023 10.1128/JVI.74.14.6581-6591.2000 10.1016/j.ebiom.2015.11.041 10.1073/pnas.2237038100 10.1016/j.jbiotec.2006.08.002 10.1016/j.biomaterials.2011.09.025 10.4161/hv.26846 10.1006/jmbi.2000.4464 10.1126/science.3798106 10.1016/j.vaccine.2014.05.064 10.1016/j.jip.2011.05.001 10.1016/j.febslet.2004.09.009 10.1080/14760584.2018.1516552 10.1080/2162402X.2017.1408746 10.1080/14712598.2020.1752177 10.1007/s11262-009-0418-2 10.1056/NEJMoa1101245 10.3390/vaccines6030037 10.1371/journal.pbio.0040003 10.1186/1475-2859-10-33 10.1016/j.virol.2004.12.036 10.1002/ijc.22527 10.1002/bit.21716 10.1586/erv.12.147 10.1371/journal.pone.0006032 10.1021/mp300211a 10.1016/j.antiviral.2019.03.012 10.1002/bit.22085 10.1134/S0026893319030154 10.1002/eji.200425547 10.3390/v12030270 10.1016/j.addr.2018.08.007 10.1021/mp3003368 10.1128/JVI.72.5.3827-3836.1998 10.1016/j.copbio.2015.12.007 10.1023/B:DOBI.0000046646.32174.84 10.1034/j.1600-065X.2000.17717.x 10.1016/0264-410X(94)00061-Q 10.1128/9781555819194.ch22 10.1016/j.smim.2017.08.014 10.1016/j.smim.2017.09.003 10.1006/jmbi.1999.3104 10.1016/j.antiviral.2016.12.019 10.1038/nbt0412-300a 10.1158/2326-6066.CIR-20-0082 10.1016/j.antiviral.2017.09.012 10.1016/j.vaccine.2013.05.019 10.1038/32588 10.1016/j.virol.2012.06.001 10.1007/s11095-015-1730-2 10.1016/S0264-410X(01)00083-4 10.1007/s00253-015-7213-x 10.1097/CJI.0b013e318209ee72 10.1006/jsre.1997.5097 10.1186/1475-2859-10-48 10.1128/JVI.75.13.6154-6165.2001 10.1002/bit.21710 10.2165/00003495-200363100-00006 10.1371/journal.pone.0018437 10.1128/JVI.00050-06 10.1128/jvi.64.4.1530-1536.1990 10.1016/j.vaccine.2013.06.039 10.1517/14712598.8.2.235 10.3390/vaccines8010139 10.1016/0092-8674(86)90071-1 10.18388/abp.2014_1875 10.1002/bit.22299 10.1038/nnano.2015.292 10.1111/pbi.12783 10.1002/elsc.202000033 10.1021/acs.molpharmaceut.9b00180 10.3390/v12010018 10.1016/j.vaccine.2015.01.031 10.1002/eji.200737984 10.1007/s12275-017-7058-3 10.3390/cancers12061492 10.1006/viro.1993.1067 10.29245/2578-3009/2018/2.1118 10.1016/S1470-2045(13)70477-7 10.1007/s00216-019-02383-z 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U 10.1006/smvy.1994.1040 10.1159/000055399 10.1039/C7RA12128H 10.1038/79758 10.1002/bip.22759 10.1016/j.vaccine.2018.08.033 10.1038/s41598-019-54928-y 10.1016/j.vaccine.2004.11.064 10.4161/hv.20042 10.3390/microorganisms8111745 10.1038/s41541-017-0006-8 10.1098/rstb.1999.0403 10.1080/14760584.2020.1738225 10.1002/pmic.201100174 10.1038/35100512 10.1038/icb.2010.161 10.1002/mas.21571 10.1007/s13353-010-0001-5 10.1021/mp3002057 10.1128/AAC.00169-06 10.1016/j.coviro.2013.05.004 10.1016/j.vaccine.2017.06.084 10.1080/2162402X.2017.1408749 10.1038/s41598-016-0001-8 10.1186/1743-422X-7-279 10.1371/journal.pone.0014538 10.1016/j.chroma.2014.05.087 10.1016/j.vaccine.2005.01.006 10.1074/jbc.M313612200 10.1016/j.jbiotec.2006.10.005 10.1002/rmv.449 10.1016/j.vaccine.2020.03.007 10.1002/ijc.20244 10.1016/j.vaccine.2006.05.082 10.1016/j.addr.2020.06.024 10.1016/j.biomaterials.2013.03.017 10.1159/000346773 10.1016/j.virol.2007.05.007 10.1542/peds.2006-0461 10.1002/bit.25159 10.1186/1472-6750-7-62 10.1128/IAI.72.11.6519-6527.2004 10.3322/caac.21492 10.1089/vim.2013.0013 10.1128/mBio.00787-17 10.1186/1743-422X-8-333 10.1186/s13568-018-0638-8 10.4143/crt.2005.37.6.319 10.1016/j.clim.2017.08.004 10.1016/j.nbt.2017.07.010 10.3389/fbioe.2020.00862 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7QO 7TB 7X7 7XB 88E 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU COVID D1I DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. KB. LK8 M0S M1P M7P P64 PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12951-021-00806-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Biotechnology Research Abstracts Mechanical & Transportation Engineering Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Biological Science Collection ProQuest Central (New) (NC LIVE) Technology collection ProQuest Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Biological Science Database (NC LIVE) Biotechnology and BioEngineering Abstracts Materials Science Collection ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Mechanical & Transportation Engineering Abstracts ProQuest Central Essentials Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection Materials Science Database ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Materials Science Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (no login required) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Open Access (no login required) url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering Chemistry |
| EISSN | 1477-3155 |
| EndPage | 27 |
| ExternalDocumentID | oai_doaj_org_article_a7045ce902764a9eaaf52953bf7bc54f PMC7905985 A653663337 33632278 10_1186_s12951_021_00806_7 |
| Genre | Journal Article Review |
| GeographicLocations | Iran |
| GeographicLocations_xml | – name: Iran |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADDVE ADMLS ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 D1I DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE I-F IAO IHR INH INR ISR ITC ITG ITH KB. KQ8 LK8 M1P M48 M7P MM. M~E O5R O5S OK1 OVT P2P PDBOC PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV RVI SCM SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QO 7TB 7XB 8FD 8FK AZQEC COVID DWQXO FR3 GNUQQ K9. P64 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c641t-9a799b9b5276986f16ff9ce0901f6352676980e0933d8296e93f2625b461aeea3 |
| IEDL.DBID | KB. |
| ISICitedReferencesCount | 561 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000624453900005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-3155 |
| IngestDate | Fri Oct 03 12:30:41 EDT 2025 Tue Nov 04 02:01:15 EST 2025 Sun Nov 09 12:12:53 EST 2025 Fri Nov 14 19:17:48 EST 2025 Tue Nov 11 10:21:34 EST 2025 Tue Nov 04 18:07:07 EST 2025 Thu Nov 13 15:04:11 EST 2025 Mon Jul 21 06:01:50 EDT 2025 Sat Nov 29 02:43:05 EST 2025 Tue Nov 18 22:29:29 EST 2025 Sat Sep 06 07:35:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Infectious disease vaccine Cancer vaccine Expression and purification platforms Immune response Subunit vaccine Virus-like particles (VLPs) |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-9a799b9b5276986f16ff9ce0901f6352676980e0933d8296e93f2625b461aeea3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2502847145?pq-origsite=%requestingapplication% |
| PMID | 33632278 |
| PQID | 2502847145 |
| PQPubID | 44676 |
| PageCount | 27 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a7045ce902764a9eaaf52953bf7bc54f pubmedcentral_primary_oai_pubmedcentral_nih_gov_7905985 proquest_miscellaneous_2494300627 proquest_journals_2502847145 gale_infotracmisc_A653663337 gale_infotracacademiconefile_A653663337 gale_incontextgauss_ISR_A653663337 pubmed_primary_33632278 crossref_citationtrail_10_1186_s12951_021_00806_7 crossref_primary_10_1186_s12951_021_00806_7 springer_journals_10_1186_s12951_021_00806_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-25 |
| PublicationDateYYYYMMDD | 2021-02-25 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of nanobiotechnology |
| PublicationTitleAbbrev | J Nanobiotechnol |
| PublicationTitleAlternate | J Nanobiotechnology |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | KA Aires (806_CR75) 2006; 72 D Kong (806_CR157) 2012; 432 C Wang (806_CR23) 2017; 140 T Zhang (806_CR92) 2005; 4 C-D Yang (806_CR96) 2007; 7 V Rolih (806_CR200) 2020; 12 E Fiebiger (806_CR165) 2001; 193 N Scotti (806_CR41) 2013; 12 Y-T Lee (806_CR22) 2018; 13 J Marsian (806_CR146) 2016; 37 A Zeltins (806_CR129) 2013; 53 J Fuenmayor (806_CR66) 2017; 39 S Bräutigam (806_CR46) 1993; 192 PJ Glass (806_CR109) 2000; 74 F Shiri (806_CR11) 2020; 412 N Munoz (806_CR185) 2004; 111 JM Galarza (806_CR116) 2005; 18 MO Mohsen (806_CR208) 2019; 7 C Peixoto (806_CR61) 2007; 127 EH Nardin (806_CR72) 2004; 72 LX Doan (806_CR147) 2005; 15 R Cubas (806_CR204) 2011; 34 E-K Yim (806_CR187) 2005; 37 MM van Oers (806_CR59) 2011; 107 A Langenkamp (806_CR168) 2000; 1 K Choi (806_CR217) 2013; 10 A Jegerlehner (806_CR224) 2002; 20 B Leyland-Jones (806_CR197) 2001; 61 MA D’Aoust (806_CR24) 2010; 8 H-Y Li (806_CR38) 2013; 31 J Ren (806_CR65) 1997; 71 G-D Chang (806_CR84) 2003; 102 JA Chichester (806_CR102) 2018; 36 A Shytuhina (806_CR122) 2014; 1364 V Manolova (806_CR160) 2008; 38 F Bray (806_CR205) 2018; 68 Y-C Chung (806_CR43) 2008; 26 806_CR104 L Conti (806_CR199) 2020; 8 Q Zeng (806_CR216) 2013; 34 806_CR107 L Zhai (806_CR192) 2017; 147 M Herbst-Kralovetz (806_CR150) 2010; 9 F Sallusto (806_CR166) 2000; 177 B Syomin (806_CR62) 2019; 53 A Link (806_CR159) 2012; 188 F Zabel (806_CR158) 2013; 3 V Cimica (806_CR19) 2017; 183 S Welsch (806_CR50) 2007; 581 C Pulcini (806_CR148) 2013; 31 CY Yuen (806_CR145) 2016; 34 DJ Slamon (806_CR194) 1987; 235 B Donaldson (806_CR67) 2015 DT Le (806_CR8) 2019; 9 Y Gu (806_CR119) 2017; 35 K O’Donnell (806_CR29) 2020; 19 H Fasehee (806_CR221) 2011; 11 SJ Dennis (806_CR99) 2018; 16 B Temizoz (806_CR114) 2016; 28 WA Rodríguez-Limas (806_CR39) 2011; 10 FA Galaway (806_CR15) 2013; 10 L Splawn (806_CR132) 2018; 54 L Shan (806_CR211) 2012; 33 T Vicente (806_CR55) 2011; 107 J Banchereau (806_CR169) 1998; 392 A Zlotnick (806_CR49) 2011; 19 GM Keating (806_CR78) 2003; 63 J Beran (806_CR139) 2008; 8 W Cai (806_CR142) 2016; 6 Y Gleba (806_CR85) 2005; 23 C Li (806_CR105) 2010; 28 MO Mohsen (806_CR12) 2018; 6 X Zhang (806_CR128) 2014; 32 DM Salunke (806_CR35) 1986; 46 PE Duffy (806_CR73) 2020; 5 SJ Win (806_CR162) 2011; 89 SL Block (806_CR79) 2006; 118 EP Rybicki (806_CR91) 2020; 12 P Walpita (806_CR156) 2011; 6 JP Langeveld (806_CR95) 2001; 19 S Zhang (806_CR58) 2011; 8 J Keene (806_CR170) 1982; 155 R Yadav (806_CR191) 2020; 12 I Balke (806_CR94) 2020; 12 I Balke (806_CR21) 2019; 145 806_CR93 KL Warfield (806_CR155) 2003; 100 AA Aljabali (806_CR215) 2013; 10 Z Zhou (806_CR153) 2011; 26 P Pushko (806_CR4) 2013; 56 F Kibenge (806_CR45) 1999; 63 CE Ashley (806_CR213) 2011; 5 H Fasehee (806_CR222) 2018; 8 J Marsian (806_CR56) 2017; 8 LF Pease III (806_CR127) 2009; 102 SM Qafari (806_CR223) 2017; 7 806_CR86 A Palladini (806_CR198) 2018; 7 E Bolli (806_CR201) 2018; 7 F Al-Barwani (806_CR161) 2014; 9 M Zdanowicz (806_CR209) 2016; 63 XS Chen (806_CR34) 2001; 307 M De Filette (806_CR74) 2006; 24 E Mortola (806_CR51) 2004; 576 N Hillebrandt (806_CR60) 2020; 8 J Weber (806_CR31) 1995; 13 S Havlikova (806_CR149) 2013; 57 S Gutiérrez-Granados (806_CR106) 2016; 100 F Fernandes (806_CR40) 2013; 12 T French (806_CR42) 1990; 64 JE Bryant (806_CR54) 2007; 366 CM Janitzek (806_CR193) 2019; 9 NF Steinmetz (806_CR3) 2010; 6 G Sailaja (806_CR7) 2007; 362 YH Joung (806_CR100) 2016; 17 TC Li (806_CR123) 2003; 311 C Qian (806_CR134) 2020; 8 H-H Pang (806_CR17) 2019; 9 L Zhai (806_CR10) 2019; 166 E Lacson (806_CR71) 2005; 9 R Kirnbauer (806_CR48) 1993; 67 B Donaldson (806_CR20) 2018; 17 806_CR77 T Latham (806_CR6) 2001; 75 M Zochowska (806_CR210) 2009; 4 806_CR64 ME Bayer (806_CR5) 1968; 218 O Lopez (806_CR115) 2007; 14 W Liu (806_CR81) 2010; 40 Z Shirbaghaee (806_CR87) 2016; 105 806_CR164 J Bessa (806_CR173) 2012; 109 H Lünsdorf (806_CR63) 2011; 10 I Yacoby (806_CR219) 2006; 50 806_CR154 C López-Macías (806_CR174) 2012; 8 TM Ross (806_CR178) 2009; 4 T Kato (806_CR16) 2015; 32 F Thiam (806_CR118) 2015; 89 VK Sharma (806_CR120) 2020; 39 B Hutchins (806_CR111) 2000; 2 T Wu (806_CR141) 2012; 8 CR Fontes-Garfias (806_CR53) 2017; 21 Q Zhao (806_CR131) 2012; 9 C Keech (806_CR28) 2020; 383 DC Parker (806_CR171) 1993; 11 T Pniewski (806_CR101) 2011; 52 806_CR190 F-C Zhu (806_CR144) 2010; 376 LM Branco (806_CR152) 2010; 7 D Fong (806_CR203) 2008; 99 806_CR188 YP Chuan (806_CR126) 2008; 99 K Namba (806_CR90) 1986; 231 Q Zhao (806_CR125) 2012; 8 MC Serradell (806_CR179) 2019; 10 JS Tregoning (806_CR25) 2020; 396 A Garg (806_CR196) 2014; 74 Z Huang (806_CR97) 2009; 103 806_CR182 L Santi (806_CR98) 2008; 26 A Naskalska (806_CR68) 2015; 64 S Saraswat (806_CR80) 2016; 10 P Lenz (806_CR176) 2005; 35 J-M Song (806_CR177) 2011; 6 M Deschuyteneer (806_CR140) 2010; 6 H Jeong (806_CR14) 2017; 55 HL Vieira (806_CR47) 2005; 120 Q Yao (806_CR175) 2004; 173 M Döring (806_CR167) 2019; 3 A Abbing (806_CR218) 2004; 279 RL Atmar (806_CR32) 2011; 365 SW Li (806_CR143) 2005; 23 Y Hu (806_CR70) 2014; 10 LW McGinnes (806_CR108) 2011; 85 MO Mohsen (806_CR207) 2019; 10 BC Bundy (806_CR37) 2008; 100 M Zochowska (806_CR212) 2015; 11 SN Crooke (806_CR220) 2019; 16 R Oropesa (806_CR124) 2013; 4 C-C Lai (806_CR110) 2019; 13 CC Joe (806_CR9) 2020; 38 P Goelet (806_CR89) 1982; 79 806_CR33 Y-L Lin (806_CR44) 2012; 30 S Rosales-Mendoza (806_CR103) 2020; 20 B Harrison (806_CR88) 1999; 354 P Lizotte (806_CR206) 2016; 11 A Proffitt (806_CR30) 2012 WR Heath (806_CR181) 2001; 1 Q Zhao (806_CR214) 2011; 22 YH Chung (806_CR2) 2020; 156 806_CR27 C-Y Wu (806_CR83) 2010; 5 BC Bundy (806_CR36) 2011; 154 M Oldstone (806_CR151) 2002; 262 PM Rudd (806_CR52) 1999; 293 S Zhang (806_CR202) 2013; 8 L Buonaguro (806_CR163) 2006; 80 S Rockman (806_CR26) 2020; 8 B Bai (806_CR1) 2008; 3 K Kondo (806_CR136) 2009; 67 J Guo (806_CR180) 2019; 10 X Huang (806_CR69) 2017; 2 RB Mandell (806_CR184) 2010; 397 M Wei (806_CR135) 2018; 7 VG Morón (806_CR172) 2003; 171 T Zhang (806_CR189) 2019; 37 806_CR18 Y Yang (806_CR121) 2015; 33 806_CR13 KA Martins (806_CR113) 2016; 3 G Bianchini (806_CR195) 2014; 15 JP Phelps (806_CR76) 2007; 128 G-JJ Chang (806_CR57) 2003; 306 F-S Quan (806_CR117) 2013; 26 806_CR133 JS Smith (806_CR186) 2007; 121 TF Baumert (806_CR82) 1998; 72 Y Yang (806_CR130) 2020; 20 806_CR138 806_CR137 LH Lua (806_CR112) 2014; 111 C Ruedl (806_CR183) 2002; 32 |
| References_xml | – volume: 581 start-page: 2089 issue: 11 year: 2007 ident: 806_CR50 publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.03.060 – volume: 54 start-page: 399 issue: 7 year: 2018 ident: 806_CR132 publication-title: Drugs Today. doi: 10.1358/dot.2018.54.7.2833984 – volume: 9 start-page: 1752 issue: 6 year: 2019 ident: 806_CR17 publication-title: Theranostics doi: 10.7150/thno.30977 – volume: 12 start-page: 225 issue: 2 year: 2013 ident: 806_CR40 publication-title: Expert Rev Vaccines doi: 10.1586/erv.12.153 – volume: 306 start-page: 170 issue: 1 year: 2003 ident: 806_CR57 publication-title: Virology. doi: 10.1016/S0042-6822(02)00028-4 – volume: 376 start-page: 895 issue: 9744 year: 2010 ident: 806_CR144 publication-title: Lancet doi: 10.1016/S0140-6736(10)61030-6 – ident: 806_CR154 doi: 10.1086/520612 – volume: 7 start-page: 1 issue: 1 year: 2019 ident: 806_CR208 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0484-x – volume: 218 start-page: 1057 issue: 5146 year: 1968 ident: 806_CR5 publication-title: Down's Synd Hepat Nat – volume: 383 start-page: 2320 issue: 24 year: 2020 ident: 806_CR28 publication-title: N Engl J Med doi: 10.1056/NEJMoa2026920 – volume: 10 start-page: 1 issue: 1 year: 2019 ident: 806_CR179 publication-title: Nat Commun doi: 10.1038/s41467-018-08265-9 – volume: 362 start-page: 331 issue: 2 year: 2007 ident: 806_CR7 publication-title: Virology doi: 10.1016/j.virol.2006.12.014 – volume: 74 start-page: 819 issue: 4 year: 2014 ident: 806_CR196 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2560-3 – volume: 5 start-page: e9784 issue: 3 year: 2010 ident: 806_CR83 publication-title: PLoS ONE doi: 10.1371/journal.pone.0009784 – volume: 188 start-page: 3724 issue: 8 year: 2012 ident: 806_CR159 publication-title: J Immunol doi: 10.4049/jimmunol.1103312 – volume: 26 start-page: 1855 issue: 15 year: 2008 ident: 806_CR43 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.01.058 – volume: 3 start-page: e2685 issue: 7 year: 2008 ident: 806_CR1 publication-title: PLoS ONE doi: 10.1371/journal.pone.0002685 – volume: 120 start-page: 72 issue: 1 year: 2005 ident: 806_CR47 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2005.03.026 – volume: 9 start-page: 1 issue: 1 year: 2012 ident: 806_CR131 publication-title: Virology J doi: 10.1186/1743-422X-9-52 – volume: 9 start-page: 367 issue: 4 year: 2005 ident: 806_CR71 publication-title: Hemodial Int doi: 10.1111/j.1492-7535.2005.01155.x – volume: 14 start-page: 269 issue: 3 year: 2007 ident: 806_CR115 publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00304-06 – volume: 13 start-page: 1 issue: 1 year: 2019 ident: 806_CR110 publication-title: J Biol Eng doi: 10.1186/s13036-019-0206-z – volume: 171 start-page: 2242 issue: 5 year: 2003 ident: 806_CR172 publication-title: J Immunol doi: 10.4049/jimmunol.171.5.2242 – volume: 10 start-page: e0004782 issue: 7 year: 2016 ident: 806_CR80 publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0004782 – volume: 17 start-page: 1715 issue: 10 year: 2016 ident: 806_CR100 publication-title: Int J Mol Sci doi: 10.3390/ijms17101715 – volume: 11 start-page: 331 issue: 1 year: 1993 ident: 806_CR171 publication-title: Annu Rev Immunol doi: 10.1146/annurev.iy.11.040193.001555 – volume: 10 start-page: 1015 year: 2019 ident: 806_CR207 publication-title: Front Immunol doi: 10.3389/fimmu.2019.01015 – volume: 2 start-page: 532 issue: 6 year: 2000 ident: 806_CR111 publication-title: Mol Ther doi: 10.1006/mthe.2000.0217 – volume: 20 start-page: 3104 issue: 25–26 year: 2002 ident: 806_CR224 publication-title: Vaccine doi: 10.1016/S0264-410X(02)00266-9 – volume: 109 start-page: 20566 issue: 50 year: 2012 ident: 806_CR173 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1206970109 – volume: 173 start-page: 1951 issue: 3 year: 2004 ident: 806_CR175 publication-title: J Immunol doi: 10.4049/jimmunol.173.3.1951 – volume: 26 start-page: 1846 issue: 15 year: 2008 ident: 806_CR98 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.01.053 – ident: 806_CR18 doi: 10.1615/CritRevTherDrugCarrierSyst.2020033273 – volume: 53 start-page: 92 issue: 1 year: 2013 ident: 806_CR129 publication-title: Mol Biotechnol doi: 10.1007/s12033-012-9598-4 – volume: 155 start-page: 768 issue: 3 year: 1982 ident: 806_CR170 publication-title: J Exp Med doi: 10.1084/jem.155.3.768 – volume: 8 start-page: 411 issue: 3 year: 2012 ident: 806_CR174 publication-title: Hum Vaccines Immunother doi: 10.4161/hv.18757 – volume: 102 start-page: 61 issue: 1 year: 2003 ident: 806_CR84 publication-title: J Biotechnol doi: 10.1016/S0168-1656(02)00364-4 – volume: 9 start-page: 299 issue: 3 year: 2010 ident: 806_CR150 publication-title: Expert Rev Vaccines doi: 10.1586/erv.09.163 – volume: 89 start-page: 27 year: 2015 ident: 806_CR118 publication-title: Microb Pathog doi: 10.1016/j.micpath.2015.08.013 – volume: 19 start-page: 14 issue: 1 year: 2011 ident: 806_CR49 publication-title: Trends Microbiol doi: 10.1016/j.tim.2010.11.003 – volume: 67 start-page: 6929 issue: 12 year: 1993 ident: 806_CR48 publication-title: J Virol doi: 10.1128/jvi.67.12.6929-6936.1993 – volume: 3 start-page: 839 issue: 6 year: 2019 ident: 806_CR167 publication-title: Blood Adv doi: 10.1182/bloodadvances.2018027268 – volume: 99 start-page: 1290 issue: 8 year: 2008 ident: 806_CR203 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604677 – volume: 30 start-page: 1305 issue: 7 year: 2012 ident: 806_CR44 publication-title: Vaccine doi: 10.1016/j.vaccine.2011.12.081 – volume: 28 start-page: 4294 issue: 26 year: 2010 ident: 806_CR105 publication-title: Vaccine doi: 10.1016/j.vaccine.2010.04.025 – volume: 9 start-page: 1 issue: 1 year: 2019 ident: 806_CR193 publication-title: Sci Rep doi: 10.1038/s41598-019-41522-5 – volume: 6 start-page: 634 issue: 5 year: 2010 ident: 806_CR3 publication-title: Nanomedicine. doi: 10.1016/j.nano.2010.04.005 – volume: 21 start-page: 1180 issue: 5 year: 2017 ident: 806_CR53 publication-title: Cell reports doi: 10.1016/j.celrep.2017.10.016 – volume: 22 start-page: 346 issue: 3 year: 2011 ident: 806_CR214 publication-title: Bioconjug Chem doi: 10.1021/bc1002532 – ident: 806_CR190 doi: 10.1128/JVI.01930-17 – volume: 18 start-page: 244 issue: 1 year: 2005 ident: 806_CR116 publication-title: Viral Immunol doi: 10.1089/vim.2005.18.244 – volume: 193 start-page: 881 issue: 8 year: 2001 ident: 806_CR165 publication-title: J Exp Med doi: 10.1084/jem.193.8.881 – volume: 397 start-page: 187 issue: 1 year: 2010 ident: 806_CR184 publication-title: Virology doi: 10.1016/j.virol.2009.11.001 – volume: 396 start-page: 1464 issue: 10261 year: 2020 ident: 806_CR25 publication-title: The Lancet doi: 10.1016/S0140-6736(20)32010-9 – volume: 107 start-page: S42 year: 2011 ident: 806_CR55 publication-title: J Invertebr Pathol doi: 10.1016/j.jip.2011.05.004 – volume: 8 start-page: 1182 issue: 7 year: 2012 ident: 806_CR125 publication-title: Nanomedicine. doi: 10.1016/j.nano.2012.01.007 – volume: 79 start-page: 5818 issue: 19 year: 1982 ident: 806_CR89 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.79.19.5818 – volume: 72 start-page: 745 issue: 1 year: 2006 ident: 806_CR75 publication-title: Appl Environ Microbiol doi: 10.1128/AEM.72.1.745-752.2006 – volume: 8 start-page: 1 issue: 1 year: 2017 ident: 806_CR56 publication-title: Nat Commun doi: 10.1038/s41467-017-00090-w – volume: 26 start-page: 338 issue: 5 year: 2011 ident: 806_CR153 publication-title: Virologica Sinica. doi: 10.1007/s12250-011-3209-6 – volume: 64 start-page: 3 issue: 1 year: 2015 ident: 806_CR68 publication-title: Polish J Microbiol. doi: 10.33073/pjm-2015-001 – volume: 8 start-page: e68303 issue: 7 year: 2013 ident: 806_CR202 publication-title: PLoS ONE doi: 10.1371/journal.pone.0068303 – volume: 231 start-page: 1401 issue: 4744 year: 1986 ident: 806_CR90 publication-title: Science. doi: 10.1126/science.3952490 – ident: 806_CR133 doi: 10.2217/17460794.3.1.83 – volume: 13 start-page: e0190868 issue: 1 year: 2018 ident: 806_CR22 publication-title: PLoS ONE doi: 10.1371/journal.pone.0190868 – volume: 11 start-page: 67 issue: 1 year: 2015 ident: 806_CR212 publication-title: Nanomedicine. doi: 10.1016/j.nano.2014.07.009 – volume: 67 start-page: 62 issue: 1 year: 2009 ident: 806_CR136 publication-title: Nihon rinsho Jpn J Clin Med – volume: 8 start-page: 607 issue: 5 year: 2010 ident: 806_CR24 publication-title: Plant Biotechnol J doi: 10.1111/j.1467-7652.2009.00496.x – volume: 85 start-page: 366 issue: 1 year: 2011 ident: 806_CR108 publication-title: J Virol doi: 10.1128/JVI.01861-10 – volume: 37 start-page: 4022 issue: 30 year: 2019 ident: 806_CR189 publication-title: Vaccine doi: 10.1016/j.vaccine.2019.06.002 – volume: 9 start-page: e104523 issue: 8 year: 2014 ident: 806_CR161 publication-title: PLoS ONE doi: 10.1371/journal.pone.0104523 – volume: 10 start-page: 592 year: 2019 ident: 806_CR180 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00592 – volume: 5 start-page: 5729 issue: 7 year: 2011 ident: 806_CR213 publication-title: ACS Nano doi: 10.1021/nn201397z – volume: 4 start-page: e5569 issue: 5 year: 2009 ident: 806_CR210 publication-title: PLoS ONE doi: 10.1371/journal.pone.0005569 – ident: 806_CR93 doi: 10.1128/JVI.00129-19 – volume: 28 start-page: 329 issue: 7 year: 2016 ident: 806_CR114 publication-title: Int Immunol doi: 10.1093/intimm/dxw015 – volume: 57 start-page: 123 issue: 2 year: 2013 ident: 806_CR149 publication-title: Acta Virol doi: 10.4149/av_2013_02_123 – volume: 154 start-page: 230 issue: 4 year: 2011 ident: 806_CR36 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2011.04.011 – volume: 311 start-page: 115 issue: 1 year: 2003 ident: 806_CR123 publication-title: Virology. doi: 10.1016/S0042-6822(03)00141-7 – volume: 12 start-page: e1587 issue: 2 year: 2020 ident: 806_CR91 publication-title: Wiley Interdiscipl Rev – ident: 806_CR27 doi: 10.12688/f1000research.18749.1 – volume: 8 start-page: 489 year: 2020 ident: 806_CR60 publication-title: Front Bioeng Biotechnol doi: 10.3389/fbioe.2020.00489 – volume: 63 start-page: 469 issue: 3 year: 2016 ident: 806_CR209 publication-title: Acta Biochim Pol doi: 10.18388/abp.2016_1275 – volume: 34 start-page: 33 issue: 1 year: 2016 ident: 806_CR145 publication-title: Vaccine doi: 10.1016/j.vaccine.2015.11.032 – volume: 6 start-page: 407 issue: 5 year: 2010 ident: 806_CR140 publication-title: Human vaccines doi: 10.4161/hv.6.5.11023 – volume: 74 start-page: 6581 issue: 14 year: 2000 ident: 806_CR109 publication-title: J Virol doi: 10.1128/JVI.74.14.6581-6591.2000 – volume: 3 start-page: 67 year: 2016 ident: 806_CR113 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2015.11.041 – volume: 100 start-page: 15889 issue: 26 year: 2003 ident: 806_CR155 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.2237038100 – volume: 127 start-page: 452 issue: 3 year: 2007 ident: 806_CR61 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2006.08.002 – volume: 33 start-page: 146 issue: 1 year: 2012 ident: 806_CR211 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2011.09.025 – volume: 10 start-page: 469 issue: 2 year: 2014 ident: 806_CR70 publication-title: Human vaccines & immunotherapeutics doi: 10.4161/hv.26846 – volume: 307 start-page: 173 issue: 1 year: 2001 ident: 806_CR34 publication-title: J Mol Biol doi: 10.1006/jmbi.2000.4464 – volume: 235 start-page: 177 issue: 4785 year: 1987 ident: 806_CR194 publication-title: Science. doi: 10.1126/science.3798106 – volume: 32 start-page: 4039 issue: 32 year: 2014 ident: 806_CR128 publication-title: Vaccine doi: 10.1016/j.vaccine.2014.05.064 – volume: 107 start-page: S3 year: 2011 ident: 806_CR59 publication-title: J Invertebr Pathol doi: 10.1016/j.jip.2011.05.001 – volume: 576 start-page: 174 issue: 1–2 year: 2004 ident: 806_CR51 publication-title: FEBS Lett doi: 10.1016/j.febslet.2004.09.009 – volume: 17 start-page: 833 issue: 9 year: 2018 ident: 806_CR20 publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2018.1516552 – volume: 7 start-page: e1408746 issue: 3 year: 2018 ident: 806_CR201 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1408746 – volume: 20 start-page: 545 issue: 6 year: 2020 ident: 806_CR103 publication-title: Exp Opin Biol Ther doi: 10.1080/14712598.2020.1752177 – volume: 40 start-page: 53 issue: 1 year: 2010 ident: 806_CR81 publication-title: Virus Genes doi: 10.1007/s11262-009-0418-2 – volume: 365 start-page: 2178 year: 2011 ident: 806_CR32 publication-title: N Engl J Med doi: 10.1056/NEJMoa1101245 – volume: 6 start-page: 37 issue: 3 year: 2018 ident: 806_CR12 publication-title: Vaccines doi: 10.3390/vaccines6030037 – volume: 4 start-page: e3 issue: 1 year: 2005 ident: 806_CR92 publication-title: PLoS Biol doi: 10.1371/journal.pbio.0040003 – volume: 10 start-page: 1 issue: 1 year: 2011 ident: 806_CR39 publication-title: Microb Cell Fact doi: 10.1186/1475-2859-10-33 – ident: 806_CR104 doi: 10.1016/j.virol.2004.12.036 – volume: 121 start-page: 621 issue: 3 year: 2007 ident: 806_CR186 publication-title: Int J Cancer doi: 10.1002/ijc.22527 – volume: 100 start-page: 28 issue: 1 year: 2008 ident: 806_CR37 publication-title: Biotechnol Bioeng doi: 10.1002/bit.21716 – volume: 12 start-page: 211 issue: 2 year: 2013 ident: 806_CR41 publication-title: Expert Rev Vaccines doi: 10.1586/erv.12.147 – volume: 4 start-page: e6032 issue: 6 year: 2009 ident: 806_CR178 publication-title: PLoS ONE doi: 10.1371/journal.pone.0006032 – volume: 10 start-page: 18 issue: 1 year: 2013 ident: 806_CR217 publication-title: Mol Pharm. doi: 10.1021/mp300211a – volume: 166 start-page: 56 year: 2019 ident: 806_CR10 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2019.03.012 – volume: 102 start-page: 845 issue: 3 year: 2009 ident: 806_CR127 publication-title: Biotechnol Bioeng doi: 10.1002/bit.22085 – volume: 53 start-page: 323 issue: 3 year: 2019 ident: 806_CR62 publication-title: Mol Biol doi: 10.1134/S0026893319030154 – volume: 35 start-page: 1548 issue: 5 year: 2005 ident: 806_CR176 publication-title: Eur J Immunol doi: 10.1002/eji.200425547 – volume: 12 start-page: 270 issue: 3 year: 2020 ident: 806_CR94 publication-title: Viruses doi: 10.3390/v12030270 – volume: 145 start-page: 119 year: 2019 ident: 806_CR21 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2018.08.007 – volume: 10 start-page: 59 issue: 1 year: 2013 ident: 806_CR15 publication-title: Mol Pharm doi: 10.1021/mp3003368 – volume: 262 start-page: 5 year: 2002 ident: 806_CR151 publication-title: Arenaviruses – volume: 72 start-page: 3827 issue: 5 year: 1998 ident: 806_CR82 publication-title: J Virol doi: 10.1128/JVI.72.5.3827-3836.1998 – volume: 37 start-page: 201 year: 2016 ident: 806_CR146 publication-title: Curr Opin Biotechnol doi: 10.1016/j.copbio.2015.12.007 – ident: 806_CR64 doi: 10.1023/B:DOBI.0000046646.32174.84 – volume: 177 start-page: 134 year: 2000 ident: 806_CR166 publication-title: Immunol Rev doi: 10.1034/j.1600-065X.2000.17717.x – volume: 13 start-page: 831 issue: 9 year: 1995 ident: 806_CR31 publication-title: Vaccine doi: 10.1016/0264-410X(94)00061-Q – ident: 806_CR164 doi: 10.1128/9781555819194.ch22 – ident: 806_CR137 doi: 10.1016/j.smim.2017.08.014 – ident: 806_CR13 doi: 10.1016/j.smim.2017.09.003 – volume: 293 start-page: 351 issue: 2 year: 1999 ident: 806_CR52 publication-title: J Mol Biol doi: 10.1006/jmbi.1999.3104 – volume: 140 start-page: 55 year: 2017 ident: 806_CR23 publication-title: Antiviral Res doi: 10.1016/j.antiviral.2016.12.019 – volume-title: First HEV vaccine approved year: 2012 ident: 806_CR30 doi: 10.1038/nbt0412-300a – volume: 8 start-page: 1039 issue: 8 year: 2020 ident: 806_CR199 publication-title: Cance Immunol Res. doi: 10.1158/2326-6066.CIR-20-0082 – ident: 806_CR182 – volume: 147 start-page: 116 year: 2017 ident: 806_CR192 publication-title: Antivir Res. doi: 10.1016/j.antiviral.2017.09.012 – volume: 31 start-page: 3281 issue: 32 year: 2013 ident: 806_CR38 publication-title: Vaccine doi: 10.1016/j.vaccine.2013.05.019 – volume: 5 start-page: 1 issue: 48 year: 2020 ident: 806_CR73 publication-title: npj Vaccines – volume: 392 start-page: 245 issue: 6673 year: 1998 ident: 806_CR169 publication-title: Nature doi: 10.1038/32588 – volume: 7 start-page: 1 issue: 1 year: 2018 ident: 806_CR135 publication-title: Emerging microbes & infections – volume: 432 start-page: 327 issue: 2 year: 2012 ident: 806_CR157 publication-title: Virology doi: 10.1016/j.virol.2012.06.001 – volume: 32 start-page: 3699 issue: 11 year: 2015 ident: 806_CR16 publication-title: Pharm Res doi: 10.1007/s11095-015-1730-2 – volume: 19 start-page: 3661 issue: 27 year: 2001 ident: 806_CR95 publication-title: Vaccine. doi: 10.1016/S0264-410X(01)00083-4 – volume: 100 start-page: 3935 issue: 9 year: 2016 ident: 806_CR106 publication-title: Applied microbiology and biotechnology. doi: 10.1007/s00253-015-7213-x – volume: 34 start-page: 251 issue: 3 year: 2011 ident: 806_CR204 publication-title: J Immunother doi: 10.1097/CJI.0b013e318209ee72 – volume: 71 start-page: 13 issue: 1 year: 1997 ident: 806_CR65 publication-title: J Surg Res doi: 10.1006/jsre.1997.5097 – volume: 10 start-page: 1 issue: 1 year: 2011 ident: 806_CR63 publication-title: Microb Cell Fact doi: 10.1186/1475-2859-10-48 – volume: 75 start-page: 6154 issue: 13 year: 2001 ident: 806_CR6 publication-title: J Virol doi: 10.1128/JVI.75.13.6154-6165.2001 – volume: 99 start-page: 1425 issue: 6 year: 2008 ident: 806_CR126 publication-title: Biotechnol Bioeng doi: 10.1002/bit.21710 – volume: 63 start-page: 1021 issue: 10 year: 2003 ident: 806_CR78 publication-title: Drugs doi: 10.2165/00003495-200363100-00006 – volume: 6 start-page: e18437 issue: 4 year: 2011 ident: 806_CR156 publication-title: PLoS ONE doi: 10.1371/journal.pone.0018437 – volume: 80 start-page: 9134 issue: 18 year: 2006 ident: 806_CR163 publication-title: J Virol doi: 10.1128/JVI.00050-06 – volume: 64 start-page: 1530 issue: 4 year: 1990 ident: 806_CR42 publication-title: J Virol doi: 10.1128/jvi.64.4.1530-1536.1990 – volume: 31 start-page: 3943 issue: 37 year: 2013 ident: 806_CR148 publication-title: Vaccine doi: 10.1016/j.vaccine.2013.06.039 – volume: 8 start-page: 235 issue: 2 year: 2008 ident: 806_CR139 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.8.2.235 – volume: 8 start-page: 139 issue: 1 year: 2020 ident: 806_CR134 publication-title: Vaccines doi: 10.3390/vaccines8010139 – volume: 46 start-page: 895 issue: 6 year: 1986 ident: 806_CR35 publication-title: Cell doi: 10.1016/0092-8674(86)90071-1 – ident: 806_CR33 doi: 10.18388/abp.2014_1875 – volume: 103 start-page: 706 issue: 4 year: 2009 ident: 806_CR97 publication-title: Biotechnol Bioeng doi: 10.1002/bit.22299 – volume: 11 start-page: 295 issue: 3 year: 2016 ident: 806_CR206 publication-title: Nat Nanotechnol doi: 10.1038/nnano.2015.292 – volume: 16 start-page: 442 issue: 2 year: 2018 ident: 806_CR99 publication-title: Plant Biotechnol J doi: 10.1111/pbi.12783 – volume: 20 start-page: 451 issue: 11 year: 2020 ident: 806_CR130 publication-title: Eng Life Sci doi: 10.1002/elsc.202000033 – volume: 16 start-page: 2947 issue: 7 year: 2019 ident: 806_CR220 publication-title: Mol Pharm doi: 10.1021/acs.molpharmaceut.9b00180 – volume: 12 start-page: 18 issue: 1 year: 2020 ident: 806_CR191 publication-title: Viruses doi: 10.3390/v12010018 – volume: 33 start-page: 1143 issue: 9 year: 2015 ident: 806_CR121 publication-title: Vaccine. doi: 10.1016/j.vaccine.2015.01.031 – volume: 38 start-page: 1404 issue: 5 year: 2008 ident: 806_CR160 publication-title: Eur J Immunol doi: 10.1002/eji.200737984 – volume: 55 start-page: 220 issue: 3 year: 2017 ident: 806_CR14 publication-title: J Microbiol doi: 10.1007/s12275-017-7058-3 – volume: 12 start-page: 1492 issue: 6 year: 2020 ident: 806_CR200 publication-title: Cancers doi: 10.3390/cancers12061492 – volume: 192 start-page: 512 issue: 2 year: 1993 ident: 806_CR46 publication-title: Virology doi: 10.1006/viro.1993.1067 – ident: 806_CR77 doi: 10.29245/2578-3009/2018/2.1118 – volume: 15 start-page: e58 issue: 2 year: 2014 ident: 806_CR195 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70477-7 – volume: 4 start-page: 025007 issue: 2 year: 2013 ident: 806_CR124 publication-title: Adv Nat Sci – volume: 412 start-page: 1563 issue: 7 year: 2020 ident: 806_CR11 publication-title: Anal Bioanal Chem doi: 10.1007/s00216-019-02383-z – volume: 32 start-page: 818 issue: 3 year: 2002 ident: 806_CR183 publication-title: Eur J Immunol doi: 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U – ident: 806_CR188 doi: 10.1006/smvy.1994.1040 – volume: 61 start-page: 31 issue: Suppl. 2 year: 2001 ident: 806_CR197 publication-title: Oncology doi: 10.1159/000055399 – volume: 7 start-page: 56006 issue: 88 year: 2017 ident: 806_CR223 publication-title: RSC Adv doi: 10.1039/C7RA12128H – volume: 1 start-page: 311 issue: 4 year: 2000 ident: 806_CR168 publication-title: Nat Immunol doi: 10.1038/79758 – volume: 105 start-page: 113 issue: 3 year: 2016 ident: 806_CR87 publication-title: Biopolymers doi: 10.1002/bip.22759 – volume: 36 start-page: 5865 issue: 39 year: 2018 ident: 806_CR102 publication-title: Vaccine doi: 10.1016/j.vaccine.2018.08.033 – volume: 9 start-page: 1 issue: 1 year: 2019 ident: 806_CR8 publication-title: Scientific reports doi: 10.1038/s41598-019-54928-y – volume: 23 start-page: 2893 issue: 22 year: 2005 ident: 806_CR143 publication-title: Vaccine doi: 10.1016/j.vaccine.2004.11.064 – volume: 8 start-page: 823 issue: 6 year: 2012 ident: 806_CR141 publication-title: Hum Vaccines Immunother doi: 10.4161/hv.20042 – volume: 8 start-page: 1745 issue: 11 year: 2020 ident: 806_CR26 publication-title: Microorganisms doi: 10.3390/microorganisms8111745 – volume: 2 start-page: 1 issue: 1 year: 2017 ident: 806_CR69 publication-title: npj Vaccines. doi: 10.1038/s41541-017-0006-8 – volume: 354 start-page: 521 issue: 1383 year: 1999 ident: 806_CR88 publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.1999.0403 – volume: 19 start-page: 267 issue: 3 year: 2020 ident: 806_CR29 publication-title: Expert Rev Vaccines doi: 10.1080/14760584.2020.1738225 – volume: 11 start-page: 3905 issue: 19 year: 2011 ident: 806_CR221 publication-title: Proteomics doi: 10.1002/pmic.201100174 – volume: 1 start-page: 126 issue: 2 year: 2001 ident: 806_CR181 publication-title: Nat Rev Immunol doi: 10.1038/35100512 – start-page: 159 volume-title: Virus-like particles, a versatile subunit vaccine platform. Subunit Vaccine Delivery year: 2015 ident: 806_CR67 – ident: 806_CR86 – volume: 89 start-page: 681 issue: 6 year: 2011 ident: 806_CR162 publication-title: Immunol Cell Biol doi: 10.1038/icb.2010.161 – volume: 39 start-page: 83 issue: 1–2 year: 2020 ident: 806_CR120 publication-title: Mass Spectrom Rev doi: 10.1002/mas.21571 – volume: 52 start-page: 125 issue: 2 year: 2011 ident: 806_CR101 publication-title: J Appl Genet doi: 10.1007/s13353-010-0001-5 – volume: 10 start-page: 3 issue: 1 year: 2013 ident: 806_CR215 publication-title: Mol Pharm doi: 10.1021/mp3002057 – volume: 50 start-page: 2087 issue: 6 year: 2006 ident: 806_CR219 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00169-06 – volume: 3 start-page: 357 issue: 3 year: 2013 ident: 806_CR158 publication-title: Curr Opin Virol doi: 10.1016/j.coviro.2013.05.004 – volume: 35 start-page: 4637 issue: 35 year: 2017 ident: 806_CR119 publication-title: Vaccine doi: 10.1016/j.vaccine.2017.06.084 – volume: 63 start-page: 49 issue: 1 year: 1999 ident: 806_CR45 publication-title: Can J Vet Res – volume: 7 start-page: e1408749 issue: 3 year: 2018 ident: 806_CR198 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1408749 – volume: 6 start-page: 1 issue: 1 year: 2016 ident: 806_CR142 publication-title: Scientific reports doi: 10.1038/s41598-016-0001-8 – volume: 7 start-page: 1 issue: 1 year: 2010 ident: 806_CR152 publication-title: Virol J doi: 10.1186/1743-422X-7-279 – volume: 6 start-page: e14538 issue: 1 year: 2011 ident: 806_CR177 publication-title: PLoS ONE doi: 10.1371/journal.pone.0014538 – volume: 1364 start-page: 192 year: 2014 ident: 806_CR122 publication-title: J Chromatogr A doi: 10.1016/j.chroma.2014.05.087 – volume: 23 start-page: 2042 issue: 17–18 year: 2005 ident: 806_CR85 publication-title: Vaccine doi: 10.1016/j.vaccine.2005.01.006 – volume: 279 start-page: 27410 issue: 26 year: 2004 ident: 806_CR218 publication-title: J Biol Chem doi: 10.1074/jbc.M313612200 – volume: 128 start-page: 290 issue: 2 year: 2007 ident: 806_CR76 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2006.10.005 – volume: 15 start-page: 75 issue: 2 year: 2005 ident: 806_CR147 publication-title: Rev Med Virol doi: 10.1002/rmv.449 – volume: 38 start-page: 3892 issue: 22 year: 2020 ident: 806_CR9 publication-title: Vaccine doi: 10.1016/j.vaccine.2020.03.007 – volume: 111 start-page: 278 issue: 2 year: 2004 ident: 806_CR185 publication-title: Int J Cancer doi: 10.1002/ijc.20244 – volume: 24 start-page: 6597 issue: 44–46 year: 2006 ident: 806_CR74 publication-title: Vaccine doi: 10.1016/j.vaccine.2006.05.082 – volume: 156 start-page: 214 year: 2020 ident: 806_CR2 publication-title: Adv Drug Deliv Rev. doi: 10.1016/j.addr.2020.06.024 – volume: 34 start-page: 4632 issue: 19 year: 2013 ident: 806_CR216 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2013.03.017 – volume: 56 start-page: 141 issue: 3 year: 2013 ident: 806_CR4 publication-title: Intervirology doi: 10.1159/000346773 – volume: 366 start-page: 415 issue: 2 year: 2007 ident: 806_CR54 publication-title: Virology doi: 10.1016/j.virol.2007.05.007 – volume: 118 start-page: 2135 issue: 5 year: 2006 ident: 806_CR79 publication-title: Pediatrics doi: 10.1542/peds.2006-0461 – volume: 111 start-page: 425 issue: 3 year: 2014 ident: 806_CR112 publication-title: Biotechnol Bioeng doi: 10.1002/bit.25159 – volume: 7 start-page: 1 issue: 1 year: 2007 ident: 806_CR96 publication-title: BMC Biotechnol doi: 10.1186/1472-6750-7-62 – volume: 72 start-page: 6519 issue: 11 year: 2004 ident: 806_CR72 publication-title: Infect Immun doi: 10.1128/IAI.72.11.6519-6527.2004 – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 806_CR205 publication-title: Cancer J Clin. doi: 10.3322/caac.21492 – volume: 26 start-page: 385 issue: 6 year: 2013 ident: 806_CR117 publication-title: Viral Immunol doi: 10.1089/vim.2013.0013 – ident: 806_CR138 doi: 10.1128/mBio.00787-17 – volume: 8 start-page: 1 issue: 1 year: 2011 ident: 806_CR58 publication-title: Virol J doi: 10.1186/1743-422X-8-333 – volume: 8 start-page: 1 issue: 1 year: 2018 ident: 806_CR222 publication-title: AMB Express. doi: 10.1186/s13568-018-0638-8 – volume: 37 start-page: 319 issue: 6 year: 2005 ident: 806_CR187 publication-title: Cancer Res Treat doi: 10.4143/crt.2005.37.6.319 – volume: 183 start-page: 99 year: 2017 ident: 806_CR19 publication-title: Clin Immunol doi: 10.1016/j.clim.2017.08.004 – volume: 39 start-page: 174 year: 2017 ident: 806_CR66 publication-title: New Biotechnol doi: 10.1016/j.nbt.2017.07.010 – ident: 806_CR107 doi: 10.3389/fbioe.2020.00862 |
| SSID | ssj0022424 |
| Score | 2.686015 |
| SecondaryResourceType | review_article |
| Snippet | Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and... Abstract Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 59 |
| SubjectTerms | Antibodies Antibodies, Neutralizing - immunology Antigens Biotechnology Cancer vaccine Cancer vaccines Chemistry Chemistry and Materials Science COVID-19 Vaccines - biosynthesis COVID-19 Vaccines - immunology COVID-19 Vaccines - therapeutic use Display devices Drug delivery Drug delivery systems Drugs Expression and purification platforms Fabrication Gene therapy Genomes Glycoproteins Health aspects Hepatitis HIV Human immunodeficiency virus Humans Immune response Immune response (cell-mediated) Immune system Immunity - physiology Immunization Immunogenicity Immunotherapy Infectious disease vaccine Infectious diseases Lipids Mammals Methods Mimicry Molecular Medicine Nanomaterials Nanoparticles Nanotechnology Preventive medicine Product development Proteins Quantum dots Review SARS-CoV-2 - immunology SARS-CoV-2 - pathogenicity Self-assembly Severe acute respiratory syndrome coronavirus 2 Structural proteins Subunit vaccine Vaccination - methods Vaccines Vaccines, Virus-Like Particle - biosynthesis Vaccines, Virus-Like Particle - immunology Vaccines, Virus-Like Particle - therapeutic use Vehicles Viral diseases Viral proteins Virus-like particles Virus-like particles (VLPs) Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QxAEOiG_KBioIiQOLtjbf3AZigsuE-NJuUZqmj4qpfWpf9_djp-3jdQi4cOglcZXUdhK7sX8m5EVpCi10MFT6LFCufElBzIEqEQrOcqNLNxabUGdn-vzcfNwp9YUxYSM88Mi4I6fA6PDBgPskuTPBuQrvplhRqcILXuHuC1bP7ExNrhYmPcwpMloe9XCqCXCbc3iAWFK1OIYiWv_ve_LOoXQ1YPLKrWk8jE5vk1uTFZmejLO_Q66F5i65uYMteI-svtXd0NOL-kdI13P42-t03YUR7bttDtMak0NaUKHagzGeuqZM48VBijGHfer6tHFYNNXj7Xsf-8tuWMVW7zosdtffJ19P3315-55OVRWolzzbUOOUMYUpBDDUaFllsqqMD8dgGFQS0fKx-Tjgn45S50YGw6ocvKSCy8yF4NgDste0TXhE0tx4n2tphMsqzkKh0X8rOGdKCEQ9TEg2M9n6CXIcK19c2Oh6aGlHwVgQjI2CsSohr7bvrEfAjb9Sv0HZbSkRLDs2gArZibf2XyqUkOcoeYtwGA3G26zc0Pf2w-dP9kQKBjYZYzDSy4moauEbvJvSF4ATiKC1oDxYUMJ69cvuWcHstF_0FgzRaCdwkZBn2258E2PgmtAOQMMRKh9hpRPycNTH7XczJhkmNSdELTR1wZhlT1N_j2jiiNBmNIx7OOv0r2n9mfGP_wfj98mNPK7JnObigOxtuiE8Idf95abuu6dxRf8EcI5MaQ priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9UwDI9gIAEHPsaAwkAFIXFgFWvzzW1MTHCZ0AbTblGapo-KqX1q9vj7sdP2sY4PCQ69JI7aOE5i1_bPhLysdKm48joTLvcZk67KYJl9JrkvGS20quxQbEIeHqrTU_1pTAoLU7T75JKMJ3Xc1kq8CXAzcTB9C3hAzRGZvEquwXWncDseHZ-szSxMeJjSY347bnYFRaT-X8_jCxfS5WDJSx7TeBEd3Pm_Kdwlt0fFM90bJOUeueLbTXJjf6r3tkluXYAmvE8WJ02_CtlZ882nyyl67m267P0AFt61O2mDuSUdSGDjQJdPbVul0e-QYshiSG1IW4s1Vx0670Psr_rVIrY622OtvLBFvhy8_7z_IRuLMmROsPw801ZqXeqSF1JoJepc1LV2fhf0ilog2D4273r8UVKpQguvaV2AkVUykVvvLX1ANtqu9Y9IWmjnCiU0t3nNqC8Vmn8lY1RyjqCJCcmndTJuRCzHwhlnJlouSpiBoQYYaiJDjUzI6_WY5YDX8Vfqd7j8a0rE2o4NXb8wI2-NlaD2Oq_BgBfMam9tjd5RWtaydJzVCXmBwmMQTaPFcJ2FXYVgPh4fmT3BKah0lMKbXo1EdQdzcHbMfgBOIADXjHJ7RglS4Obdk4ya8bgJBvTYqGYwnpDn624ciSF0re9WQMMQaR9RqRPycBDp9bwpFRRzohMiZ8I-Y8y8p22-RjByBHjTCt67M4n8z8_6M-Mf_xv5E3KziLumyAq-TTbO-5V_Sq677-dN6J_F7f8D-d9T4Q priority: 102 providerName: Springer Nature |
| Title | Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers |
| URI | https://link.springer.com/article/10.1186/s12951-021-00806-7 https://www.ncbi.nlm.nih.gov/pubmed/33632278 https://www.proquest.com/docview/2502847145 https://www.proquest.com/docview/2494300627 https://pubmed.ncbi.nlm.nih.gov/PMC7905985 https://doaj.org/article/a7045ce902764a9eaaf52953bf7bc54f |
| Volume | 19 |
| WOSCitedRecordID | wos000624453900005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Directory of Open Access Journals (no login required) customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: M7P dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: KB. dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Open Access (no login required) customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1477-3155 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0022424 issn: 1477-3155 databaseCode: RSV dateStart: 20031201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLfYxgEOfH8ERhUQEgcWtsTxFxe0ok1MiKrqYCony3GcEjElJW75-_Fzkm4ZYhcOrVT7Ran9nt-H_fx7CL3ORcYJNyKiOjZRynQeOTabiBGTpTgRPFdtsQk2mfD5XEy7DTfbpVX2OtEr6rzWsEe-70y116Qp-bD8FUHVKDhd7UpobKEdQEmA0g2fx-82ARdcfegvynC6b51tIy54TtzHOUo0YgNj5DH7_9bMl0zT1bTJK2en3iQd3_3fwdxDdzpnNDxspec-umGqB-j2JYjCh2hxVjZrG52XP0247LPo3ofLxrSg4XW1F5Zwx6R2klhq59OHqspDf_4QQuqiDZUNKwW1VzUc4lvfnzfrhW_VqoGaefYR-nZ89PXjp6grzhBpmsarSCgmRCYykjAqOC1iWhRCmwPnXxQUQPeh-cDAhknOE0GNwEXigq0spbEyRuHHaLuqK_MUhYnQOuFUEBUXKTYZhzAwS1PMCAHwxADFPZek7pDLoYDGufQRDKey5ax0nJWes5IF6O3mmWWL23Et9RiYv6EEzG3fUDcL2c2tVMy5v9oIF8jTVAmjVAGnpDgrWKZJWgToFYiOBFSNCtJ2FmptrTw5nclDSrBz7TB2b3rTERW1G4NW3S0INxMAxDWg3B1QumWvh929aMlO7Vh5IVcBernphichla4y9drRpIC4D-jUAXrSCvRm3BhTDHejA8QGoj6YmGFPVf7woOQA9Ca4e-9evygu_ta_J_7Z9aN4jm4lfrkmUUJ20faqWZsX6Kb-vSptM0JbbM78Nx-hnfHRZDob-T2VkVcDI8jjnbqe6cmX6Xf3a3Z69gdCPmHg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQQIOvB-BAgGBONCou3Zix0gIlUfVVcsKQUF7M47jLBFVsiS7IP4Uv5EZJ9ltiuitBw652JNkx5mHZz3zDSGPU5nEUWxlwM3QBqEwaQCf2QYisknIqIxT3TSbEONxPJnI92vkd1cLg2mVnU10hjotDf5HvgWu2lnSMHo5-x5g1yg8Xe1aaDRisWd__YSQrX4xegPf9wmlO28PXu8GbVeBwPBwOA-kFlImMomo4DLm2ZBnmTR2AI4x44gWj8MDi5F-GlPJrWQZhSghCflQW6sZPPcMOQt2XGAKmZisAjwstegKc2K-VYMvjSBYp3DBxowHouf8XI-Avz3BEVd4PE3z2Fmtc4E7l_-3xbtCLrWbbX-70Y6rZM0W18jFIxCM18n0c14t6uAw_2b9WZcl-NyfVbYBRS-LTT_HGpoSNC03ELP4ukh9d77iY2pm7evaLzT2ljWYpFC7-bRaTN2o0RX2BKxvkE-nwulNsl6Uhb1NfCqNoTGXkR5mIbNJjGFuEoZMRBGCQ3pk2EmFMi0yOzYIOVQuQou5aiRJgSQpJ0lKeOTZ8p5Zg0tyIvUrFLYlJWKKu4Gymqp2bZUWsL03Vg6A41BLq3WGp8AsyURiojDzyCMUVYWoIQWmJU31oq7V6OMHtc0jBltXxuBNT1uirAQejG6rPGAlEGisR7nRowSzZvrTnSir1qzWaiXHHnm4nMY7MVWwsOUCaELsKIDo2x651SjQkm_GOMPab4-Inmr1FqY_U-RfHeg6AtnJGN672Snh6mf9e-HvnMzFA3J-9-DdvtofjffukgvUmQoa0GiDrM-rhb1Hzpkf87yu7jtD45Mvp62cfwBQiLO8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIAoHHuUVKBAQEgcatYnf3EphRQVaVRSq3izHsbcRVbJKdvn9eJxk2ZSHhDjkYo-VeDy2ZzIz3yD0spC5oMLKhJnUJoSbIvHLbBNObU5wJkWhu2ITfDoVp6fyaC2LP0S7Dy7JLqcBUJqqxe68cN0WF2y39bcU9WZw5h-v8rCEX0ZXCBQNAnv9-GRlckHyw5Aq89txo-sooPb_ejavXU4XAycveE_DpTS59f_TuY1u9gppvN9J0B10yVZbaPNgqAO3hW6sQRbeRbOTslm2yXn5zcbzIaruTTxvbAciXlc7cQk5J7WXzNJ4HT_WVREHf0QMoYxtrNu40lCL1YBTvw39RbOchVajG6ih195DXyfvvxx8SPpiDYlhJF0kUnMpc5nTjDMpmEuZc9LYPa9vOAYg_NC8Z-EHSiEyyazELvPGV05Yqq3V-D7aqOrKPkRxJo3JBJNUp45gmwswC3NCMKcUwBQjlA5rpkyPZA4FNc5VsGgEUx1DlWeoCgxVPEKvV2PmHY7HX6nfgiisKAGDOzTUzUz1vFWae3XYWOkNe0a0tFo78Jri3PHcUOIi9AIESQHKRgVhPDO9bFt1ePxZ7TOKvaqHsX_Tq57I1X4ORvdZEZ4TAMw1otweUXopMOPuQV5Vfwy1yuu3Qf0gNELPV90wEkLrKlsvPQ0BBH5Aq47Qg068V_PGmGHIlY4QHwn-iDHjnqo8CyDlAPwmhX_vziD-Pz_rz4x_9G_kz9C1o3cT9elw-vExup6FDZQlGd1GG4tmaZ-gq-b7omybp-FU-AGyK1-p |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Virus-like+particles%3A+preparation%2C+immunogenicity+and+their+roles+as+nanovaccines+and+drug+nanocarriers&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Nooraei%2C+Saghi&rft.au=Bahrulolum%2C+Howra&rft.au=Hoseini%2C+Zakieh+Sadat&rft.au=Katalani%2C+Camellia&rft.date=2021-02-25&rft.pub=BioMed+Central&rft.eissn=1477-3155&rft.volume=19&rft_id=info:doi/10.1186%2Fs12951-021-00806-7&rft_id=info%3Apmid%2F33632278&rft.externalDocID=PMC7905985 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon |